{"id":432533,"date":"2021-02-10T04:11:06","date_gmt":"2021-02-10T09:11:06","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=432533"},"modified":"2021-02-10T04:11:06","modified_gmt":"2021-02-10T09:11:06","slug":"immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/","title":{"rendered":"Immunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n LUND, Sweden<\/span>, Feb. 10, 2021<\/span> \/PRNewswire\/ —\u00a0Immunovia\u00a0AB (publ) (“Immunovia”) today provides an update on the status of the company’s activities and as previously reported (<\/b>Webinar Dec 17, 2020<\/span><\/a>), Immunovia will initiate sales start in Q1 2021 of the company’s first test, IMMray\u2122 PanCan-d designed for early detection of pancreatic cancer.<\/b><\/p>\n

Since the last update, Immunovia’s R&D and production departments in Lund<\/span> have been working at full speed to ensure the highest quality reagents and arrays are available for the final blind validation study of IMMray\u2122 PanCan-d. All the necessary samples for the blind validation study have been secured and will be analyzed in Marlborough<\/span> in Q1. <\/p>\n

The dedicated Immunovia Dx Laboratory in Marlborough<\/span>, USA<\/span> has recently completed implementation of its quality system and is now in the final preparation stages prior to performing the blind validation study leading up to a Q1 sales start followed by accreditation and commercial testing in Q2 2021. <\/p>\n

Immunovia’s commercial team have full focus on the marketing and launch activities in the USA<\/span> to achieve our sales start of IMMray\u2122 PanCan-d in Q1.<\/p>\n

“We are very grateful to our collaborators who collected all the necessary samples for the final step before commercialization, the blind validation study. Immunovia personnel have been working uninterrupted, living up to our values of dedication and commitment despite all the challenges presented daily during these times. We are now looking forward to commercialization start of our first test, IMMray\u2122 PanCan-d and to working with healthcare providers to more effectively detecting pancreatic cancer in its early stages thus making a significant difference for the affected patients”, says Patrik Dahlen<\/span>, CEO Immunovia.<\/p>\n

\n For more information, please contact:<\/b>
\n
\n Patrik Dahlen<\/span>, CEO, Immunovia
Email: patrik.dahlen@immunovia.com<\/a>
Tel: +46 73 376 76 64<\/p>\n

\n About Immunovia<\/b>
\n
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on\u00a0Immunovia’s proprietary test platform called IMMray\u2122.\u00a0Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.<\/p>\n

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund<\/span> University and CREATE Health Cancer Center, Sweden<\/span>.<\/p>\n

The first product, IMMray\u2122 PanCan-d, is undergoing clinical evaluation in some of the\u00a0world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1<\/a>\u00a0and is currently in the final validation phase. The company aims for a sales start at the end of Q1 2021 with subsequent commercial testing in Q2. <\/p>\n

When validated, IMMray\u2122 PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.<\/p>\n

Immunovia Dx Laboratories located in Marlborough, Massachusetts<\/span>, USA and Lund, Sweden<\/span> will provide laboratory testing services in two accredited reference laboratories. <\/p>\n

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com<\/a>.<\/p>\n

This information was brought to you by Cision http:\/\/news.cision.com<\/a><\/p>\n

\n https:\/\/news.cision.com\/immunovia-ab\/r\/immunovia-on-track-for-immray–pancan-d-sales-start-in-q1-2021,c3283641<\/a>\n <\/p>\n

The following files are available for download:<\/p>\n

\n\n\n
\n

\n
\n https:\/\/mb.cision.com\/Main\/13121\/3283641\/1370633.pdf<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Press release (PDF)<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\u00a0<\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021-301225677.html<\/a><\/p>\n

SOURCE Immunovia AB<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire LUND, Sweden, Feb. 10, 2021 \/PRNewswire\/ —\u00a0Immunovia\u00a0AB (publ) (“Immunovia”) today provides an update on the status of the company’s activities and as previously reported (Webinar Dec 17, 2020), Immunovia will initiate sales start in Q1 2021 of the company’s first test, IMMray\u2122 PanCan-d designed for early detection of pancreatic cancer. Since the last update, Immunovia’s R&D and production departments in Lund have been working at full speed to ensure the highest quality reagents and arrays are available for the final blind validation study of IMMray\u2122 PanCan-d. All the necessary samples for the blind validation study have been secured and will be analyzed in Marlborough in Q1. The dedicated Immunovia Dx Laboratory in Marlborough, USA has recently completed implementation … <\/p>\n

Continue reading “Immunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-432533","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LUND, Sweden, Feb. 10, 2021 \/PRNewswire\/ —\u00a0Immunovia\u00a0AB (publ) (“Immunovia”) today provides an update on the status of the company’s activities and as previously reported (Webinar Dec 17, 2020), Immunovia will initiate sales start in Q1 2021 of the company’s first test, IMMray\u2122 PanCan-d designed for early detection of pancreatic cancer. Since the last update, Immunovia’s R&D and production departments in Lund have been working at full speed to ensure the highest quality reagents and arrays are available for the final blind validation study of IMMray\u2122 PanCan-d. All the necessary samples for the blind validation study have been secured and will be analyzed in Marlborough in Q1. The dedicated Immunovia Dx Laboratory in Marlborough, USA has recently completed implementation … Continue reading "Immunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-10T09:11:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO75985&sd=2021-02-10\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021\",\"datePublished\":\"2021-02-10T09:11:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\\\/\"},\"wordCount\":560,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO75985&sd=2021-02-10\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\\\/\",\"name\":\"Immunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO75985&sd=2021-02-10\",\"datePublished\":\"2021-02-10T09:11:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO75985&sd=2021-02-10\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO75985&sd=2021-02-10\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/","og_locale":"en_US","og_type":"article","og_title":"Immunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021 - Market Newsdesk","og_description":"PR Newswire LUND, Sweden, Feb. 10, 2021 \/PRNewswire\/ —\u00a0Immunovia\u00a0AB (publ) (“Immunovia”) today provides an update on the status of the company’s activities and as previously reported (Webinar Dec 17, 2020), Immunovia will initiate sales start in Q1 2021 of the company’s first test, IMMray\u2122 PanCan-d designed for early detection of pancreatic cancer. Since the last update, Immunovia’s R&D and production departments in Lund have been working at full speed to ensure the highest quality reagents and arrays are available for the final blind validation study of IMMray\u2122 PanCan-d. All the necessary samples for the blind validation study have been secured and will be analyzed in Marlborough in Q1. The dedicated Immunovia Dx Laboratory in Marlborough, USA has recently completed implementation … Continue reading \"Immunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-10T09:11:06+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO75985&sd=2021-02-10","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021","datePublished":"2021-02-10T09:11:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/"},"wordCount":560,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO75985&sd=2021-02-10","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/","name":"Immunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO75985&sd=2021-02-10","datePublished":"2021-02-10T09:11:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO75985&sd=2021-02-10","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO75985&sd=2021-02-10"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-on-track-for-immray-pancan-d-sales-start-in-q1-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immunovia On Track For IMMray\u2122 PanCan-d Sales Start In Q1 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/432533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=432533"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/432533\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=432533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=432533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=432533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}